Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark
DAHANCA Proton Feasibility Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In preparation for a randomised study in Denmark (DAHANCA 35) the feasibility of selecting newly diagnosed patients with squamous cell carcinoma of the pharynx or larynx for proton therapy at the local treatment centers is investigated. A proton and a photon doseplan is prepared for patients planned for primary radiotherapy . If proton radiotherapy reduces the anticipated absolute risk of dysphagia >= grade 2 (DAHANCA scale and/or xerostomia >= grade 2 (EORTC Head-Neck 35) with a clinical relevant value the patient is offered proton therapy at the Danish Center for Particle Therapy. The anticipated risk of xerostomia and dysphagia is estimated using Normal-Tissue Complication Models (NTCP).
At least five patients from each of the six Danish centers are required in this feasibility study.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Aalborg, Danmark
- Aalborg University Hospital
-
Aarhus, Danmark
- Aarhus University Hospital
-
Aarhus, Danmark
- Danish Center for Particle Therapy
-
Copenhagen, Danmark
- Rigshospitalet
-
Herlev, Danmark
- Herlev Hospital
-
Næstved, Danmark
- Næstved Hospital
-
Odense, Danmark
- Odense University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent
A predicted clinical significant reduction in the risk of any of the two primary endpoints (>= grade 2 observer-rated dysphagia or grade 2 patient-reported xerostomia) after proton therapy compared to photon therapy based on comparison of the individual patient dose plans
No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer
Informed consent as required by law
Above 18 years of age
Exclusion Criteria:
Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area, nasopharynx, unknown primary tumor and prior malignancies.
Patients with contraindications for proton therapy (as per 2019 pacemakers, implanted defibrillators and tracheostomy)
Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic
Distant metastasis
Previous radiotherapy of the head and neck
Previous surgery for the primary cancer with curative intent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Proton radiotherapy
Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA).
Treatment: 66-68 Gy/ 33-34 fx/ 6/W,with cisplatin 40 mg/m2/W and nimorazole to suitable patients
|
Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA).
Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dysfagi >= grad 2
Tidsramme: Seks måneder etter avsluttet strålebehandling
|
Frekvensen av observatørrapportert dysfagi >= grad 2 målt ved DAHANCA sen toksisitetsscore (grad 0-4, hvor 0 er best)
|
Seks måneder etter avsluttet strålebehandling
|
|
Xerostomia = grade 2
Tidsramme: Six months after end of radiotherapy
|
The rate of patient-reported xerostomia measured by the EORTC Quality of life questionnaire (QLQ) Head-Neck (HN) 35 (grade 1-4, with 1 being best)
|
Six months after end of radiotherapy
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Loco-regional tumor control
Tidsramme: Up to five years after end of radiotherapy
|
Time to event of local-regional failure, from date of randomization to the date of first documented loco-regional failure. Rates are estimated by the Kaplan-Meier method. Interim analyses after 100, 200 and 300 patients. Will not be reported before the primary endpoint. |
Up to five years after end of radiotherapy
|
|
Overall survival
Tidsramme: Up to five years after end of radiotherapy]
|
From date of randomisation to date of death
|
Up to five years after end of radiotherapy]
|
|
Acute toxicity
Tidsramme: From the beginning of and up to two months after end of radiotherapy]
|
DAHANCA acute toxicity score (grade 0-4, 0 being best)
|
From the beginning of and up to two months after end of radiotherapy]
|
|
Late toxicity
Tidsramme: From two months to five years after end of radiotherapy]
|
DAHANCA late toxicity score (grade 0-4, 0 being best)
|
From two months to five years after end of radiotherapy]
|
|
EORTC QLQ-Head-Neck 35
Tidsramme: Up to five years after end of radiotherapy
|
Swallowing and social-eating scale and specific HN35 items related to eating and pain (grade 1-4, 1 being best)
|
Up to five years after end of radiotherapy
|
|
EORTC C30
Tidsramme: Up to five years after end of radiotherapy]
|
Specific C30 items related to fatigue, nausea and vomiting (grade 1-4, 1 being best)
|
Up to five years after end of radiotherapy]
|
|
Time from referral to treatment
Tidsramme: From date of referral to proton treatment to first proton treatment (Assessed up to 60 days)
|
Time from referral to proton center to first proton treatment
|
From date of referral to proton treatment to first proton treatment (Assessed up to 60 days)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Jeppe Friborg, MD, PhD, Danish Head-Neck Cancer Group (DAHANCA)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DAHANCA proton feasibility
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .